PathoVax

PathoVax is a biotech start-up from Johns Hopkins commercializing RGVax, the world’s first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant types. Current vaccines target some cancer-causing HPVs and only focus on sexual transmitted types, resulting in low uptake due to the incomplete coverage and social stigma. Established animal studies have confirmed RGVax’s protection against all 15 oncogenic types and the added coverage against skin HPVs positions RGVax as a childhood vaccine, allowing unrivalled early market entry in a segment with superior uptake.